Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984202283> ?p ?o ?g. }
- W2984202283 endingPage "1603" @default.
- W2984202283 startingPage "1590" @default.
- W2984202283 abstract "While amino acid restriction remains an attractive strategy for cancer therapy, metabolic adaptations limit its effectiveness. Here we demonstrate a role of translational reprogramming in the survival of asparagine-restricted cancer cells. Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA. MAPK inhibition attenuates translational induction of ATF4 and the expression of its target asparagine synthetase (ASNS), sensitizing melanoma and pancreatic tumours to asparagine restriction, reflected in inhibition of their growth. Correspondingly, low ASNS expression is among the top predictors of response to inhibitors of MAPK signalling in patients with melanoma and is associated with favourable prognosis when combined with low MAPK signalling activity. These studies reveal an axis of adaptation to asparagine deprivation and present a rationale for clinical evaluation of MAPK inhibitors in combination with asparagine restriction approaches." @default.
- W2984202283 created "2019-11-22" @default.
- W2984202283 creator A5007334127 @default.
- W2984202283 creator A5008199007 @default.
- W2984202283 creator A5011100851 @default.
- W2984202283 creator A5011530890 @default.
- W2984202283 creator A5026512599 @default.
- W2984202283 creator A5045212145 @default.
- W2984202283 creator A5051357520 @default.
- W2984202283 creator A5054046984 @default.
- W2984202283 creator A5054591138 @default.
- W2984202283 creator A5060636893 @default.
- W2984202283 creator A5063492133 @default.
- W2984202283 creator A5087641795 @default.
- W2984202283 date "2019-11-18" @default.
- W2984202283 modified "2023-09-27" @default.
- W2984202283 title "Translational reprogramming marks adaptation to asparagine restriction in cancer" @default.
- W2984202283 cites W1493490914 @default.
- W2984202283 cites W1570622790 @default.
- W2984202283 cites W1578523240 @default.
- W2984202283 cites W1675501108 @default.
- W2984202283 cites W1961339080 @default.
- W2984202283 cites W1965542498 @default.
- W2984202283 cites W1967355018 @default.
- W2984202283 cites W1971176613 @default.
- W2984202283 cites W1980195461 @default.
- W2984202283 cites W1984791165 @default.
- W2984202283 cites W1986308117 @default.
- W2984202283 cites W1987798277 @default.
- W2984202283 cites W1999390452 @default.
- W2984202283 cites W2007725129 @default.
- W2984202283 cites W2023981106 @default.
- W2984202283 cites W2031344967 @default.
- W2984202283 cites W2032666422 @default.
- W2984202283 cites W2036865860 @default.
- W2984202283 cites W2037513168 @default.
- W2984202283 cites W2058709111 @default.
- W2984202283 cites W2071849521 @default.
- W2984202283 cites W2072319964 @default.
- W2984202283 cites W2081329333 @default.
- W2984202283 cites W2086434836 @default.
- W2984202283 cites W2089429128 @default.
- W2984202283 cites W2090406819 @default.
- W2984202283 cites W2099505694 @default.
- W2984202283 cites W2106119346 @default.
- W2984202283 cites W2112013596 @default.
- W2984202283 cites W2116978375 @default.
- W2984202283 cites W2122537353 @default.
- W2984202283 cites W2132519593 @default.
- W2984202283 cites W2136735760 @default.
- W2984202283 cites W2137522359 @default.
- W2984202283 cites W2148915086 @default.
- W2984202283 cites W2152974197 @default.
- W2984202283 cites W2163042952 @default.
- W2984202283 cites W2213025375 @default.
- W2984202283 cites W2237475663 @default.
- W2984202283 cites W2311257231 @default.
- W2984202283 cites W2322378248 @default.
- W2984202283 cites W2343975196 @default.
- W2984202283 cites W2419460319 @default.
- W2984202283 cites W2461089329 @default.
- W2984202283 cites W2461427403 @default.
- W2984202283 cites W2463069668 @default.
- W2984202283 cites W2503851771 @default.
- W2984202283 cites W2514159675 @default.
- W2984202283 cites W2577256604 @default.
- W2984202283 cites W2607135274 @default.
- W2984202283 cites W2613470058 @default.
- W2984202283 cites W2736470274 @default.
- W2984202283 cites W2775215876 @default.
- W2984202283 cites W2783201301 @default.
- W2984202283 cites W2783383798 @default.
- W2984202283 cites W2785559034 @default.
- W2984202283 cites W2785892239 @default.
- W2984202283 cites W2796317691 @default.
- W2984202283 cites W2809699427 @default.
- W2984202283 cites W2884856991 @default.
- W2984202283 cites W2886137594 @default.
- W2984202283 cites W2891362794 @default.
- W2984202283 cites W2907984739 @default.
- W2984202283 cites W2949793499 @default.
- W2984202283 cites W2955312672 @default.
- W2984202283 cites W4231565327 @default.
- W2984202283 cites W4235363258 @default.
- W2984202283 doi "https://doi.org/10.1038/s41556-019-0415-1" @default.
- W2984202283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7307327" @default.
- W2984202283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31740775" @default.
- W2984202283 hasPublicationYear "2019" @default.
- W2984202283 type Work @default.
- W2984202283 sameAs 2984202283 @default.
- W2984202283 citedByCount "53" @default.
- W2984202283 countsByYear W29842022832020 @default.
- W2984202283 countsByYear W29842022832021 @default.
- W2984202283 countsByYear W29842022832022 @default.
- W2984202283 countsByYear W29842022832023 @default.
- W2984202283 crossrefType "journal-article" @default.
- W2984202283 hasAuthorship W2984202283A5007334127 @default.
- W2984202283 hasAuthorship W2984202283A5008199007 @default.